Posters & Publications :: ProMIS Neurosciences, Inc. (PMN)

Years of Research at Your Fingertips

ProMIS Neurosciences’ publications and posters provide ample background on our research surrounding neurodegenerative diseases.

PMN310 | Amyloid-Beta

Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies

Discovery

Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration

PMN310 | Amyloid-Beta

Selective targeting and protection against toxic amyloid-beta oligomers by PMN310, a monoclonal antibody rationally designed for greater therapeutic potency in Alzheimer’s disease

PMN311 | AD Vaccine

Rational design of a vaccine for Alzheimer’s disease using a computationallyderived conformational epitope to selectively target toxic amyloid-beta oligomers

PMN311 | AD Vaccine

AAN 2023 Presentation – Rational design of a vaccine for Alzheimer’s disease using computationally-derived conformational B cell epitopes to selectively target toxic amyloid-beta oligomers

Discovery

AAN 2023 Poster – RACK1 Knockdown is a Potential Therapeutic Target in ALS and FTLD-TDP

PMN310 | Amyloid-Beta

AAN 2023 Poster – Protection against toxic amyloid-beta oligomers by PMN310 in Alzheimer’s disease

PMN310 | Amyloid-Beta

AD/PD 2023 Poster - Ability to selectively target toxic brain oligomers despite competing monomers and plaque

PMN442 | Alpha-Synuclein

Rational Generation of Monoclonal Antibodies Selective for Pathogenic Forms of Alpha-Synuclein

PMN310 | Amyloid-Beta

A Rationally Designed Humanized Antibody selective for Amyloid Beta oligomers in Alzheimer’s

PMN310 | Amyloid-Beta

Supplemental Section - A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease

PMN310 | Amyloid-Beta

AAIC 2022 Poster - Distinguishing between amyloid-beta-directed antibodies: Ability of PMN310 to target toxic oligomers despite competing species